Certara Reports Third Quarter 2024 Financial Results
06 nov. 2024 16h15 HE
|
Certara
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal...
Certara to Participate in the Stephens Annual Investment Conference
28 oct. 2024 16h15 HE
|
Certara
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the...
Certara Appoints John Reynders as New Independent Board Member
16 oct. 2024 16h15 HE
|
Certara
Certara today announced the appointment of John Reynders, PhD to its Board of Directors, effective October 15, 2024.
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
09 oct. 2024 16h15 HE
|
Certara
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third...
Certara Completes Acquisition of Chemaxon
02 oct. 2024 16h15 HE
|
Certara
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
Certara’s Simcyp Consortium Celebrates 25th Anniversary
24 sept. 2024 08h00 HE
|
Certara
Certara, a global leader in model-informed drug development, today announced the celebration of the 25th anniversary of the Simcyp® Consortium.
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
18 sept. 2024 08h00 HE
|
Certara
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.
Certara to Participate in Upcoming Investor Conferences
21 août 2024 16h15 HE
|
Certara
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the...
Certara Launches Phoenix™ Version 8.5 Drug Development Software
15 août 2024 16h15 HE
|
Certara
Certara today announced the launch of Phoenix™ version 8.5 software, the pharmaceutical industry's gold standard in PK/PD modeling and simulation.
Certara Reports Second Quarter 2024 Financial Results
06 août 2024 16h15 HE
|
Certara
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal...